Related Experiment Videos
Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease
Jan G Schiltz1, Ulrich Salzer, M Hasan Mohajeri
1Institute if Medical Virology, University of Zurich, Gloriastrasse 30, 8028 Zurich, Switzerland.
Journal of Molecular Medicine (Berlin, Germany)
|July 9, 2004
Summary
Researchers developed a novel DNA-peptide vaccine for Alzheimer's disease (AD). This vaccine effectively generated antibodies that reduced amyloid plaques in mouse models, offering a promising therapeutic strategy for AD.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alzheimer's disease (AD) neuropathology involves amyloid-beta (Abeta) peptide accumulation from amyloid precursor protein (APP) cleavage.
- Current therapeutic strategies for AD are limited, necessitating novel approaches targeting Abeta.
- Understanding Abeta aggregation and clearance is crucial for developing effective AD treatments.
Purpose of the Study:
- To develop and evaluate a novel DNA-peptide vaccine for Alzheimer's disease.
- To assess the efficacy of active immunization using a combined DNA-peptide vaccine in reducing Abeta pathology.
- To investigate the potential of monoclonal antibodies derived from the vaccine for passive immunization therapies.
Main Methods:
- Mice were vaccinated with plasmid DNA encoding human Abeta42 peptide and low doses of preaggregated peptide.
- Antibody titers and specificity were analyzed, including reactivity against Abeta aggregates and amyloid plaques.
- Transgenic AD mice were subjected to passive immunization with immune sera and monoclonal antibodies.
Main Results:
- The DNA-peptide vaccine rapidly induced detectable antibody titers within 2 weeks.
- Generated antibodies recognized Abeta aggregates in vitro and amyloid plaques in transgenic mouse brains.
- Passive immunization significantly reduced brain amyloid plaques in transgenic AD mice within 24 hours.
Conclusions:
- The combined DNA-peptide vaccine shows potential for active immunization with reduced inoculation and peptide dose, potentially mitigating inflammatory reactions.
- Monoclonal antibodies derived from this approach are suitable for passive immunization studies and may offer a therapeutic avenue for Alzheimer's disease.